InvestSMART

Invex Therapeutics Ltd (ASX: IXC) - Announcements

- Current share price for IXC : $0.085

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Notice of AGM/Proxy Form/Notice of Access 4 Nov 2026 12:26PM $0.090 $0.085 fallen by 5.56%
$7 Section 708A Cleansing Notice 30 Oct 2026 2:56PM $0.100 $0.085 fallen by 15%
$7 Application for quotation of securities - IXC 30 Oct 2026 2:48PM $0.100 $0.085 fallen by 15%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Oct 2026 12:06PM $0.100 $0.085 fallen by 15%
$7 Proposed issue of securities - IXC 26 Oct 2026 9:42AM $0.105 $0.085 fallen by 19.05%
$7 Proposed issue of securities - IXC 26 Oct 2026 9:42AM $0.105 $0.085 fallen by 19.05%
$7 Proposed issue of securities - IXC 26 Oct 2026 9:42AM $0.105 $0.085 fallen by 19.05%
$7 Invex to Acquire Rekover Therapeutics 26 Oct 2026 9:42AM $0.105 $0.085 fallen by 19.05%
$7 Trading Halt 22 Oct 2026 9:20AM $0.105 $0.085 fallen by 19.05%
$7 Notice of Annual General Meeting/Proxy Form 21 Oct 2026 1:28PM $0.105 $0.085 fallen by 19.05%
$7 AGM Date and Closing Date for Director Nominations 25 Sep 2026 5:20PM $0.110 $0.085 fallen by 22.73%
$7 Appendix 4G and Corporate Governance Statement 31 Aug 2026 7:18PM $0.110 $0.085 fallen by 22.73%
$7 Appendix 4E and Annual Report to shareholders 31 Aug 2026 7:17PM $0.110 $0.085 fallen by 22.73%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 23 Jul 2026 6:14PM $0.120 $0.085 fallen by 29.17%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 24 Apr 2026 12:13PM $0.100 $0.085 fallen by 15%
$7 Invex to Expand Preclinical Research Program 24 Apr 2026 8:11AM $0.100 $0.085 fallen by 15%
$7 Resignation of Joint Company Secretary 23 Mar 2026 12:27PM $0.100 $0.085 fallen by 15%
$7 Results of Meeting 17 Feb 2026 6:40PM $0.120 $0.085 fallen by 29.17%
$7 Appendix 4D and Half Year Report 12 Feb 2026 1:34PM $0.120 $0.085 fallen by 29.17%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 22 Jan 2026 4:16PM $0.115 $0.085 fallen by 26.09%
$7 Notice of Annual General Meeting/Proxy Form 16 Jan 2026 12:38PM $0.115 $0.085 fallen by 26.09%
$7 Deferral of Annual General Meeting 20 Nov 2025 8:23PM $0.120 $0.085 fallen by 29.17%
$7 Initial Director's Interest Notice x 2 10 Nov 2025 1:02PM $0.110 $0.085 fallen by 22.73%
$7 Reinstatement to Quotation 10 Nov 2025 9:38AM $0.115 $0.085 fallen by 26.09%
$7 Board and Officer Appointments and Company Address Change 10 Nov 2025 9:37AM $0.115 $0.085 fallen by 26.09%

1 - 25 of 310 results

Page 1 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.